<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093740</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000301</org_study_id>
    <nct_id>NCT03093740</nct_id>
  </id_info>
  <brief_title>Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant</brief_title>
  <official_title>Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label single center study for the donation of HCV positive kidneys to HCV negative
      recipients with interventional treatment to prevent HCV transmission upon transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to determine if the administration of direct acting antivirals for
      12-16 weeks after kidney transplantation prevents the spread of HCV infection from donor
      kidney with known HCV infection (all genotypes) to an HCV negative recipient as evidenced by
      a negative HCV viral RNA at 12 weeks post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Based on the genotype and viral resistance testing of the donor, that will be determined within the first week, we will initiate a genotype specific regimen for HCV treatment as available by prescription</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV RNA</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Negative HCV viral load 12 weeks after last dose of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Failure Chronic</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>HCV treatment - no viral resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV treatment - viral resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zepatier</intervention_name>
    <description>Based on negative viral resistance testing of the donor treatment will be Zepatier</description>
    <arm_group_label>HCV treatment - no viral resistance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zepatier plus Sofosbuvir</intervention_name>
    <description>Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir</description>
    <arm_group_label>HCV treatment - viral resistance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Donor meets MGH transplant center criteria and already listed for isolated kidney
             transplant

          -  No available living kidney donor

          -  Recipient has ≤ 730 days of accrued transplant waiting time

          -  Recipient chronic hemodialysis or peritoneal dialysis

          -  Recipient must agree to birth control.

             °.Weigh ≥ 50kg

          -  Serum ALT within normal limits

          -  Subject's Insurance company approves payment for DAA therapy post-kidney transplant

        Exclusion Criteria:

          -  AB Blood type

          -  HCV genotype 1

          -  BMI &gt; 35

          -  Any liver disease in recipient

          -  Pregnant or nursing (lactating) women

          -  Known allergy or intolerance to tacrolimus that would require administration of
             cyclosporine

          -  Albumin &lt; 3g/dl or

          -  Platelet count &lt; 75 x 103/mL

          -  Positive crossmatch or positive donor specific antibodies

          -  HCV RNA positive

          -  Hepatitis B surface antigen positive

          -  Patients with primary focal segmental glomerulosclerosis (FSGS)

          -  Any contra-indication to kidney transplantation per our center protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenna Gustafson, MS</last_name>
    <phone>617-724-3836</phone>
    <email>JLGustafson@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond T. Chung, MD</investigator_full_name>
    <investigator_title>Director, Hepatology, Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>renal failure</keyword>
  <keyword>kidney transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Elbasvir-grazoprevir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plans to share participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

